Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Monte Rosa Therapeutics Inc GLUE

Healthcare Biotechnology
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called... see more

Recent & Breaking News (NDAQ:GLUE)

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

GlobeNewswire March 20, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

GlobeNewswire March 11, 2025

Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 24, 2025

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

GlobeNewswire January 10, 2025

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2025

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

GlobeNewswire December 13, 2024

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire December 11, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

GlobeNewswire December 11, 2024

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

GlobeNewswire December 5, 2024

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire November 26, 2024

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 13, 2024

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2024

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire October 28, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

GlobeNewswire October 23, 2024

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

GlobeNewswire August 19, 2024

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

GlobeNewswire July 8, 2024

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

GlobeNewswire June 27, 2024

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

GlobeNewswire June 14, 2024